Abortion pills for sale in Bawshar

How Does the Abortion Pill Work? The "Abortion Pills in Bawshar" is a regimen of two different drugs, mifepristone (branded Mifeprex, also known as RU-486) and misoprostol. The abortion pill typically costs 150 Oman Riyal-650 Oman Riyal.

Mifepristone is a single pill taken to begin the medical abortion process. It functions as a progesterone antagonist, blocking the body's natural pro-gestational hormone from getting to the baby. Without adequate progesterone, fetal development stops and the baby starves if it is small enough. The farther along in a pregnancy the woman is, the less likely it is that mifepristone will end the life of the baby.

Misoprostol is the second drug in the medical abortion process, typically administered 48 hours later. Misoprostol softens the cervix and causes uterine contractions to expel the contents of the uterus. If mifepristone has not ended the life of the baby, expelling it will. Passing the uterine contents typically occurs within a few hours or up to 2 weeks though bleeding may occur for up to two weeks.

The FDA requires a physical exam 7-14 days later to confirm complete abortion and ensure that there are no immediate complications. Abortion pills are very safe and effective to use in Oman, Bawshar. Cytotec pills in Bawshar Oman, Misoprostol and Mifepristone pills in Bawshar Oman.

Risks and Side Effects

As a general rule, the bigger the baby the riskier the abortion procedure, whether medical or surgical. The farther along in pregnancy, the greater the risk.

• Common side effects include cramping, nausea, vomiting, diarrhea, heavy bleeding. In rare cases, serious infection and death can occur.
• the procedure is unsuccessful <3.2% of the time prior to 57 days, 6.5% from 57-63 days, and 7.2% from 63-70 days gestation.1
• Major adverse events requiring going to the emergency room occur for about 3.7% (about 1 in 25) of the patients between 47-63 days and 4.6% (about 1 in 20) of the patients between 64-70 days gestation.2
• Not advised for women who have anemia, bleeding disorders, liver or kidney disease, seizure disorder, acute inflammatory bowel disease, use an intrauterine device (IUD), or are unable to return for the follow-up visit.